→
Revvity Inc (RVTY) currently trades at $95.33, reflecting a modest increase of 0.56% from the previous close of $94.80. The company has shown a revenue growth of 4.79% year-over-year, but its EPS has decreased by 10.65% over the same period, indicating potential profitability concerns. Additionally, the stock has a P/E ratio of 44.19, which appears high compared to the industry average, suggesting limited upside potential at this valuation level.
Investors should hold RVTY shares until there are clearer signs of improving profitability and growth.
If Revvity can improve its earnings per share and sustain revenue growth, it could attract more investor interest, especially given its recent earnings beats in Q1 2026 with $1.06 compared to an estimate of $1.0365. Moreover, the company’s expansion into the endocrine diagnostics market with an FDA-cleared testosterone assay could drive future sales growth.
The significant decline in EPS by 10.65% year-over-year raises concerns about the company's profitability trajectory, which could deter investors. Furthermore, the current P/E ratio of 44.19 indicates that the stock may be overvalued, especially if revenue growth does not accelerate beyond the current 4.79%.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Helm's AI rates RVTY as Neutral. Investors should hold RVTY shares until there are clearer signs of improving profitability and growth.
The significant decline in EPS by 10.65% year-over-year raises concerns about the company's profitability trajectory, which could deter investors. Furthermore, the current P/E ratio of 44.19 indicates that the stock may be overvalued, especially if revenue growth does not accelerate beyond the current 4.79%.
If Revvity can improve its earnings per share and sustain revenue growth, it could attract more investor interest, especially given its recent earnings beats in Q1 2026 with $1.06 compared to an estimate of $1.0365. Moreover, the company’s expansion into the endocrine diagnostics market with an FDA-cleared testosterone assay could drive future sales growth.
Revvity Inc (RVTY) currently trades at $95.33, reflecting a modest increase of 0.56% from the previous close of $94.80. The company has shown a revenue growth of 4.79% year-over-year, but its EPS has decreased by 10.65% over the same period, indicating potential profitability concerns. Additionally, the stock has a P/E ratio of 44.19, which appears high compared to the industry average, suggesting limited upside potential at this valuation level.
Revvity Inc (RVTY) currently trades at $95.33, reflecting a modest increase of 0.56% from the previous close of $94.80. The company has shown a revenue growth of 4.79% year-over-year, but its EPS has decreased by 10.65% over the same period, indicating potential profitability concerns. Additionally, the stock has a P/E ratio of 44.19, which appears high compared to the industry average, suggesting limited upside potential at this valuation level. Our overall verdict is Neutral.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for RVTY at helmterminal.dev/analyze/RVTY, updated continuously during US market hours. No signup required.